New AI tool promises faster vaccine development by predicting T cell epitopes

Plus, news about blue­bird bio, Q32 Bio and Aque­s­tive Ther­a­peu­tics: Edge­wood On­col­o­gy’s $20M Se­ries A: The Brook­line, MA-based biotech plans to use the mon­ey to

Re­pub­li­can rep­re­sen­ta­tives lead­ing the House Com­mit­tee on Over­sight and Ac­count­abil­i­ty to­day an­nounced an in­ves­ti­ga­tion in­to FDA’s re­sponse to crit­i­cal US drug short­ages, in­clud­ing com­mon can­cer